CG 7060

Drug Profile

CG 7060

Alternative Names: ARCA CN706; CN 706; CV 706

Latest Information Update: 24 Jan 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cell Genesys
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 14 Dec 2002 Discontinued - Phase-II for Prostate cancer in USA (Intratumoural)
  • 13 Aug 2001 Definitive agreement for Cell Genesys' acquisition of Calydon signed
  • 10 Nov 2000 Results of a clinical study have been added to the adverse events section and Cancer therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top